Showing results (2991-3000 of 3,353) with videos related to

Sort By:
Pageof 336
Pharmacoeconomics|November 20, 2019
A Review of Health Economic Studies Comparing Traditional and Massively Parallel Sequencing Diagnostic Pathways for Suspected Genetic DisordersPatrick Fahr, James Buchanan, Sarah Wordsworth
Pharmacoeconomics|November 10, 2019
TECH-VER: A Verification Checklist to Reduce Errors in Models and Improve Their CredibilityNasuh C Büyükkaramikli, Maureen P M H Rutten-van Mölken, Johan L Severens, et al.
Pharmacoeconomics|November 12, 2019
Development and Validation of the TRansparent Uncertainty ASsessmenT (TRUST) Tool for Assessing Uncertainties in Health Economic Decision ModelsSabine E Grimm, Xavier Pouwels, Bram L T Ramaekers, et al.
Pharmacoeconomics|December 10, 2019
Durvalumab for the Treatment of Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology AppraisalWillem J A Witlox, Antoinette D I van Asselt, Robert Wolff, et al.
Pharmacoeconomics|November 26, 2019
How Uncertain is the Survival Extrapolation? A Study of the Impact of Different Parametric Survival Models on Extrapolated Uncertainty About Hazard Functions, Lifetime Mean Survival and Cost EffectivenessBen Kearns, John Stevens, Shijie Ren, et al.
Pharmacoeconomics|November 7, 2019
Cost-Effectiveness of Tenofovir Alafenamide for Treatment of Chronic Hepatitis B in CanadaFeng Tian, Sherilyn K D Houle, Mhd Wasem Alsabbagh, et al.
Pharmacoeconomics|December 20, 2019
Cost-Utility Analyses of Interventions for Informal Carers: A Systematic and Critical ReviewWilfried Guets, Hareth Al-Janabi, Lionel Perrier
Pharmacoeconomics|March 18, 2020
A Comparison of the EQ-5D-3L and EQ-5D-5LAlexander James Thompson, Alex James Turner
Pharmacoeconomics|March 24, 2020
Development of Population Tariffs for the CarerQol Instrument for Hungary, Poland and Slovenia: A Discrete Choice Experiment Study to Measure the Burden of Informal CaregivingPetra Baji, Miklós Farkas, Dominik Golicki, et al.
Pharmacoeconomics|March 24, 2020
The Accuracy and Usefulness of the National Comprehensive Cancer Network Evidence Blocks Affordability RatingAaron P Mitchell, Pranammya Dey, Jennifer A Ohn, et al.
Pageof 336